Krishna K Ananda, Rao G Venkateshwara, Rao Krs Sambasiva
Acharya Nagarjuna University, Center for Biotechnology, Guntur, Andhra Pradesh, India.
Regen Med. 2007 Mar;2(2):171-7. doi: 10.2217/17460751.2.2.171.
Diabetes mellitus is the most common metabolic disorder, which occurs in two forms: Type 1 diabetes (juvenile or insulin-dependent diabetes mellitus) and Type 2 diabetes (adult or noninsulin-dependent diabetes mellitus). Type 1 diabetes mellitus is a T-cell-mediated, organ-specific autoimmune disorder, in which the body's own immune system attacks beta-cells and damages them sufficiently resulting in reduced insulin production. To overcome autoimmunity, immunosuppressive therapy, gene therapy, islet cell regeneration or encapsulation of islet cells offer dramatic treatment solutions. At present, efforts for finding ways to replace damaged insulin-secreting beta-cells by implanting new cells is an active field of research. Various therapeutic strategies are under investigation and stem cell-based therapy with the combination of other treatments offers exciting possibilities for the development of treatment for such diseases. In the current review, we focus on stem cells and their potential clinical applications and summarize the recent progress in this field.
糖尿病是最常见的代谢紊乱疾病，有两种形式：1型糖尿病（青少年或胰岛素依赖型糖尿病）和2型糖尿病（成人或非胰岛素依赖型糖尿病）。1型糖尿病是一种由T细胞介导的器官特异性自身免疫性疾病，机体自身免疫系统攻击β细胞并对其造成足够损害，导致胰岛素分泌减少。为克服自身免疫，免疫抑制疗法、基因疗法、胰岛细胞再生或胰岛细胞封装提供了显著的治疗方案。目前，通过植入新细胞来替代受损的胰岛素分泌β细胞的研究是一个活跃的领域。各种治疗策略正在研究中，基于干细胞的疗法与其他治疗方法相结合为这类疾病的治疗发展提供了令人兴奋的可能性。在本综述中，我们重点关注干细胞及其潜在的临床应用，并总结该领域的最新进展。
